- Home
- PGNY vs TARS Comparison
PGNY vs TARS Comparison
Compare PGNY & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGNY
- TARS
- Stock Information
- Founded
- PGNY 2008
- TARS 2016
- Country
- PGNY United States
- TARS United States
- Employees
- PGNY N/A
- TARS N/A
- Industry
- PGNY Misc Health and Biotechnology Services
- TARS Medicinal Chemicals and Botanical Products
- Sector
- PGNY Health Care
- TARS Health Care
- Exchange
- PGNY Nasdaq
- TARS Nasdaq
- Market Cap
- PGNY 2.0B
- TARS 1.7B
- IPO Year
- PGNY 2019
- TARS 2020
- Fundamental
- Price
- PGNY $23.25
- TARS $57.88
- Analyst Decision
- PGNY Buy
- TARS Strong Buy
- Analyst Count
- PGNY 8
- TARS 7
- Target Price
- PGNY $26.14
- TARS $67.14
- AVG Volume (30 Days)
- PGNY 1.1M
- TARS 689.6K
- Earning Date
- PGNY 08-07-2025
- TARS 08-06-2025
- Dividend Yield
- PGNY N/A
- TARS N/A
- EPS Growth
- PGNY N/A
- TARS N/A
- EPS
- PGNY 0.58
- TARS N/A
- Revenue
- PGNY $1,241,968,000.00
- TARS $295,521,000.00
- Revenue This Year
- PGNY $9.92
- TARS $33,170.29
- Revenue Next Year
- PGNY $9.82
- TARS N/A
- P/E Ratio
- PGNY $39.44
- TARS N/A
- Revenue Growth
- PGNY 9.62
- TARS 254.45
- 52 Week Low
- PGNY $13.39
- TARS $25.82
- 52 Week High
- PGNY $26.76
- TARS $58.95
- Technical
- Relative Strength Index (RSI)
- PGNY 52.66
- TARS 74.75
- Support Level
- PGNY $22.26
- TARS $56.04
- Resistance Level
- PGNY $23.41
- TARS $58.95
- Average True Range (ATR)
- PGNY 0.92
- TARS 1.95
- MACD
- PGNY -0.00
- TARS 0.41
- Stochastic Oscillator
- PGNY 67.00
- TARS 90.89
About PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.